A team of UK-based investigators explored the long-term cardiovascular outcomes in patients with obesity who were administered orlistat therapy.
Each 1 mg/dL rise in uric acid level was significantly associated with a 21% and 10% increased risk for cardiovascular and all-cause mortality, respectively, a study found.
Risk for adverse events attributable to statins low when used for primary prevention of cardiovascular disease
In contrast, much higher event rate seen for racial and ethnic minorities randomly assigned to drug therapy in CABANA trial
The FDA conducted a comprehensive review of all available data associated with the use of statins during pregnancy.
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
In a small study, approximately a third of kidney transplant recipients had anemia and half had persistent secondary hyperparathyroidism.
Risk for death significantly reduced with prior statin and/or antihypertensive use among those with history of CVD and/or hypertension
No evidence of effect modification seen in interaction analyses using polygenic score with seven polymorphisms, CYP1A2 rs762551 alone
Treating iron deficiency in patients with chronic kidney disease may be necessary even in the absence of anemia, according to investigators.